Showing 5651-5660 of 19383 results for "".
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
https://reachmd.com/programs/project-oncology/unmet-needs-endometrial-cancer-treatment-equity/39929/Endometrial cancer is rising in incidence, with mortality now surpassing that of ovarian cancer. Hear from Dr. Brian Slomovitz as he explores evolving molecular classifications, treatment challenges, and the urgent need to address racial disparities in care. Dr. Slomovitz is the Director of GynecoloCadherin-6 in Focus: Existing Antibodies, Emerging Applications
https://reachmd.com/programs/living-rheum/cadherin-6-in-focus-existing-antibodies-emerging-applications/32796/While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discussesReal-World Effectiveness of Liraglutide for Obesity: Multicenter Data From Turkey
https://reachmd.com/programs/clinicians-roundtable/real-world-effectiveness-of-liraglutide-for-obesity-multicenter-data-from-turkey/39655/A large retrospective study across 38 endocrinology clinics in Turkey showed that liraglutide led to meaningful weight loss and metabolic improvements—even at slightly reduced doses. Hear from ReachMD's Ryan Quigley as he reviews recent real-world data on this GLP-1 receptor agonist.Managing Genotype-Positive Patients in Hereditary ATTR-CM
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/managing-genotype-positive-patients-in-hereditary-attr-cm/39316/Hereditary transthyretin amyloid cardiomyopathy (ATTRv-CM) can pose unique challenges for clinicians, particularly when it comes to treating genotype-positive individuals without overt symptoms. That's why a recent study explored the clinical characteristics, progression, and outcomes of family membA Case Presentation of Prurigo Nodularis
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituAdvancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
https://reachmd.com/programs/frontlines-multiple-sclerosis/advancing-ms-care-diagnostic-clarity-early-action-and-patient-centered-treatment/36391/With the latest revisions to the McDonald criteria and new therapies on the horizon, multiple sclerosis (MS) care is entering a pivotal phase. In this expert-led discussion, Dr. Gates Colbert sits down with Dr. Tirisham Gyang to unpack how emerging diagnostic tools, earlier intervention strategies,mRNA-1283 and the Future of COVID-19 Vaccination Strategies
https://reachmd.com/programs/clinicians-roundtable/mrna-1283-and-the-future-of-covid-19-vaccination-strategies/36421/While the mRNA-1283 COVID-19 vaccine shows comparable safety and immune response to its predecessor, mRNA-1273, its true clinical advantage remains under investigation, and depends in part on its integration into wider vaccination plans. Learn how this evolving vaccine technology may influence futurDWTV Extra: Rocatinlimab Trials
https://reachmd.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aCAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
https://reachmd.com/programs/project-oncology/car-t-and-bispecifics-in-lbcl-redefining-second-line-therapy-choices/35457/This is a non-certified educational series produced and controlled by ReachMD. The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only forPostcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
https://reachmd.com/programs/clinicians-roundtable/postcolonoscopy-colorectal-cancer-optimizing-quality-to-reduce-risk/36552/As fecal immunochemical testing (FIT) becomes more common in colorectal cancer screening, questions remain about post-FIT follow-up, especially when colonoscopies yield negative results. To explore this further, a recent review looked at the risk of colorectal cancer postcolonoscopy and analyzed the